APA (7th ed.) Citation

Lonardi, S., Pietrantonio, F., Prete, A., Messina, M., Formica, V., Corsi, D., . . . Zagonel, V. (2020). 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. Annals of Oncology, 31, S412. https://doi.org/10.1016/j.annonc.2020.08.513

Chicago Style (17th ed.) Citation

Lonardi, S., et al. "402MO Final Results of the CARACAS Study: Randomized Phase II Trial of Avelumab Alone or with Cetuximab for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma Progressed to at Least One Line of Treatment." Annals of Oncology 31 (2020): S412. https://doi.org/10.1016/j.annonc.2020.08.513.

MLA (9th ed.) Citation

Lonardi, S., et al. "402MO Final Results of the CARACAS Study: Randomized Phase II Trial of Avelumab Alone or with Cetuximab for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma Progressed to at Least One Line of Treatment." Annals of Oncology, vol. 31, 2020, p. S412, https://doi.org/10.1016/j.annonc.2020.08.513.